Accenture and the National Cancer Institute held a panel at the American Society of Clinical Oncology (ASCO) annual meeting to discuss personalized medicine and offer insights into more efficient clinical trials for the life sciences industry.
Two panels were convened to discuss the challenges of this new era in depth. The first panel was on diagnostic tools and how they are used in the real world, with a focus on efforts coordinated at the national level. The second panel focused on contemporary models of observational trials and their potential.
Both discussions included qualified experts from academia, industry and public agencies and were further augmented with questions and insights from the diverse group of session attendees. These conversations are summarized in the executive summary document.